Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2017

08.08.2017 | Clinical trial

Long-term peripheral neuropathy symptoms in breast cancer survivors

verfasst von: Moaath Mustafa Ali, Machelle Moeller, Lisa Rybicki, Halle C. F. Moore

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Peripheral neuropathy (PN) is a common and distressing complication from chemotherapy. Symptoms often, but not always, improve with time. The prevalence of long-term PN symptoms in breast cancer survivors is not well known. We sought to explore PN symptoms and associated risk factors among breast cancer survivors at least 2 years out from diagnosis.

Methods

We performed a cross-sectional retrospective study investigating the prevalence of patient-reported numbness, tingling, and anesthesia symptoms as a surrogate for PN in breast cancer survivors. We included patients with stage 0–III breast cancer who completed a clinical questionnaire at a survivorship visit that occurred 2 or more years after diagnosis. We estimated the prevalence of PN and identified risk factors for PN.

Results

Six hundred and five patients assessed between April 2009 and October 2016 met eligibility for analysis. Median age was 60 years. Median number of years from diagnosis to assessment was 6.3. All patients had surgery and 62% had chemotherapy. Twenty-seven percent reported PN. On univariable analysis, obesity, stage II and III, mastectomy, PN before diagnosis, and receipt of taxane chemotherapy were associated with higher risk of PN (all p < 0.05); older age, exercise, ER-positive disease, and endocrine therapy were associated with lower risk of PN (all p < 0.05). On multivariable analysis, only receipt of docetaxel (OR 2.18, CI 1.22–3.88) or paclitaxel (OR 4.07, CI 2.54–6.50) and reporting PN symptoms before diagnosis (OR 3.28, CI 1.49–7.21) were associated with higher risk of PN. Overall, 17, 20, 31, and 44% reported long-term PN symptoms after no chemotherapy, non-taxane chemotherapy, docetaxel chemotherapy, and paclitaxel chemotherapy, respectively.

Conclusion

Long-term peripheral neuropathy symptoms are reported by a significant minority of breast cancer survivors, particularly following paclitaxel or docetaxel chemotherapy. These study findings can help inform patients and clinicians regarding long-term PN risk following chemotherapy.
Literatur
1.
Zurück zum Zitat Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38(14):1832–1837CrossRefPubMed Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38(14):1832–1837CrossRefPubMed
2.
Zurück zum Zitat Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10(3):407–417CrossRefPubMed Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10(3):407–417CrossRefPubMed
3.
Zurück zum Zitat England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64(2):199–207. doi:10.1212/01.wnl.0000149522.32823.ea CrossRefPubMed England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64(2):199–207. doi:10.​1212/​01.​wnl.​0000149522.​32823.​ea CrossRefPubMed
4.
Zurück zum Zitat Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol 28(5):500–507CrossRefPubMed Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol 28(5):500–507CrossRefPubMed
6.
Zurück zum Zitat Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269CrossRefPubMed Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269CrossRefPubMed
7.
Zurück zum Zitat Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848. doi:10.1155/2012/913848 PubMedPubMedCentral Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848. doi:10.​1155/​2012/​913848 PubMedPubMedCentral
8.
Zurück zum Zitat Jud SM, Hatko R, Maihofner C, Bani MR, Schrauder MG, Lux MP, Beckmann MW, Bani G, Eder I, Fasching PA, Loehberg CR, Rauh C, Hein A (2014) Comprehensive visualization of paresthesia in breast cancer survivors. Arch Gynecol Obstet 290(1):135–141. doi:10.1007/s00404-014-3164-1 CrossRefPubMed Jud SM, Hatko R, Maihofner C, Bani MR, Schrauder MG, Lux MP, Beckmann MW, Bani G, Eder I, Fasching PA, Loehberg CR, Rauh C, Hein A (2014) Comprehensive visualization of paresthesia in breast cancer survivors. Arch Gynecol Obstet 290(1):135–141. doi:10.​1007/​s00404-014-3164-1 CrossRefPubMed
9.
Zurück zum Zitat Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774. doi:10.1007/s10549-010-1278-0 CrossRefPubMed Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774. doi:10.​1007/​s10549-010-1278-0 CrossRefPubMed
10.
Zurück zum Zitat Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132–138. doi:10.1007/s10147-011-0352-x CrossRefPubMed Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132–138. doi:10.​1007/​s10147-011-0352-x CrossRefPubMed
11.
Zurück zum Zitat Mustafa Ali M, Moeller M, Rybicki L, Moore HC (2017) Prevalence and correlates of patient-reported symptoms and comorbidities in breast cancer survivors at a tertiary center. J Cancer Survivorship. doi:10.1007/s11764-017-0612-5 Mustafa Ali M, Moeller M, Rybicki L, Moore HC (2017) Prevalence and correlates of patient-reported symptoms and comorbidities in breast cancer survivors at a tertiary center. J Cancer Survivorship. doi:10.​1007/​s11764-017-0612-5
13.
Zurück zum Zitat Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMed
14.
Zurück zum Zitat Mayer DK, Nekhlyudov L, Snyder CF, Merrill JK, Wollins DS, Shulman LN (2014) American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract Am Soc Clin Oncol 10(6):345–351. doi:10.1200/jop.2014.001321 CrossRef Mayer DK, Nekhlyudov L, Snyder CF, Merrill JK, Wollins DS, Shulman LN (2014) American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract Am Soc Clin Oncol 10(6):345–351. doi:10.​1200/​jop.​2014.​001321 CrossRef
16.
Zurück zum Zitat Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N (2012) Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel+epirubicin and cyclophosphamide. Acta Oncol 51(8):1036–1044. doi:10.3109/0284186x.2012.692884 CrossRefPubMed Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N (2012) Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel+epirubicin and cyclophosphamide. Acta Oncol 51(8):1036–1044. doi:10.​3109/​0284186x.​2012.​692884 CrossRefPubMed
18.
Zurück zum Zitat Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. doi:10.1016/j.pain.2014.09.020 CrossRefPubMed Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. doi:10.​1016/​j.​pain.​2014.​09.​020 CrossRefPubMed
19.
20.
Zurück zum Zitat Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. doi:10.3389/fphar.2017.00086 PubMedPubMedCentral Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. doi:10.​3389/​fphar.​2017.​00086 PubMedPubMedCentral
21.
Zurück zum Zitat Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264CrossRefPubMed Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264CrossRefPubMed
Metadaten
Titel
Long-term peripheral neuropathy symptoms in breast cancer survivors
verfasst von
Moaath Mustafa Ali
Machelle Moeller
Lisa Rybicki
Halle C. F. Moore
Publikationsdatum
08.08.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4437-8

Weitere Artikel der Ausgabe 2/2017

Breast Cancer Research and Treatment 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.